METTL5 and cardiac hypertrophy: Multiple key pathways of cardiac hypertrophy, such as Adrenegic signaling and MAPK signaling, were significantly altered in the KEGG analyses, that showed an opposite direction of alteration in si-METTL5 treated NRVMs vs. Ad-METTL5 treated NRVMs (Figure 4E).